These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26083653)

  • 1. Sclerostin and DKK1: new players in renal bone and vascular disease.
    Evenepoel P; D'Haese P; Brandenburg V
    Kidney Int; 2015 Aug; 88(2):235-40. PubMed ID: 26083653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
    Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
    Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
    de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
    Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients.
    Tomei P; Zaza G; Granata S; Gatti D; Fraccarollo C; Gesualdo L; Boschiero L; Lupo A
    Transplant Proc; 2014 Sep; 46(7):2241-6. PubMed ID: 25242761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
    Ke HZ; Richards WG; Li X; Ominsky MS
    Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis.
    Napimoga MH; Nametala C; da Silva FL; Miranda TS; Bossonaro JP; Demasi AP; Duarte PM
    J Clin Periodontol; 2014 Jun; 41(6):550-7. PubMed ID: 24576302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients.
    Wang YP; Sidibé A; Fortier C; Desjardins MP; Ung RV; Kremer R; Agharazii M; Mac-Way F
    J Nephrol; 2023 May; 36(4):969-978. PubMed ID: 36715822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic toxicity and sclerostin in chronic kidney disease patients.
    Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
    Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.